Pulmonary Hypertension in Lymphangioleiomyomatosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-08-31

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a descriptive study of patients with Lymphangioleiomyomatosis and precapillary pulmonary hypertension.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Descriptive study of patients with Lymphangioleiomyomatosis and precapillary pulmonary hypertension This will include modality of diagnosis of lLymphangioleiomyomatosis, results of right-sided heart catheterization, and pulmonary function tests

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphangioleiomyomatosis Pulmonary Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Lymphangioleiomyomatosis (definite or probable), either sporadic or associated with tuberous sclerosis
* Precapillary pulmonary hypertension, as defined by right-sided heart catheterization (mean pulmonary artery pressure higher than 25 mmHg, wedge capillary pulmonary pressure less than 15 mmHg, pulmonary vascular resistance higher than 3 Wood units)

Exclusion Criteria

* Post capillary pulmonary hypertension
* Other identifiable causes of pulmonary hypertension (ex: thromboembolic disease)
* Not willing to participate

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Vincent COTTIN

Pr Cottin, Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Vincent Cottin, MD

Role: PRINCIPAL_INVESTIGATOR

University of Lyon

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Louis Pradel Hospital

Lyon, University of Lyon, France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GERMOP-001

Identifier Type: -

Identifier Source: org_study_id